Penn Medicine Abramson Cancer Center


 

New Agents in R/R Large Cell Lymphoma: Pola + BR Promising Treatment, Blinatumomab and Lenalidomide Have Limited Efficacy, & Mosunetuzumab Monotherapy Achieves CR in High-Risk Pts

96 views
February 25, 2020
0 Comments
Login to view comments. Click here to Login